Loading...
CELU logo

Celularity Inc.NasdaqCM:CELU Stock Report

Market Cap US$22.2m
Share Price
US$0.78
My Fair Value
n/a
1Y-58.5%
7D-18.5%
Portfolio Value
​
View

Celularity Inc.

NasdaqCM:CELU Stock Report

Market Cap: US$22.2m

Celularity (CELU) Stock Overview

A regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. More details

CELU fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Risk Analysis

Negative shareholders equity

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($22M)


CELU Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Celularity Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Celularity
Historical stock prices
Current Share PriceUS$0.78
52 Week HighUS$4.35
52 Week LowUS$0.71
Beta0.45
1 Month Change-38.86%
3 Month Change-37.88%
1 Year Change-58.48%
3 Year Change-85.07%
5 Year Change-99.23%
Change since IPO-99.21%

Recent News & Updates

Analysis Article • Dec 15

There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding

With a price-to-sales (or "P/S") ratio of 1.1x Celularity Inc. ( NASDAQ:CELU ) may be sending very bullish signals at...

Recent updates

Analysis Article • Dec 15

There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding

With a price-to-sales (or "P/S") ratio of 1.1x Celularity Inc. ( NASDAQ:CELU ) may be sending very bullish signals at...
Analysis Article • Aug 14

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 59%

NasdaqCM:CELU 1 Year Share Price vs Fair Value Explore Celularity's Fair Values from the Community and select yours...
Analysis Article • Feb 21

Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry

You may think that with a price-to-sales (or "P/S") ratio of 0.8x Celularity Inc. ( NASDAQ:CELU ) is definitely a stock...
Analysis Article • Feb 14

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

The Celularity Inc. ( NASDAQ:CELU ) share price has done very well over the last month, posting an excellent gain of...
Seeking Alpha • Oct 03

Celularity appoints Adrian Kilcoyne as chief medical officer

Celularity (NASDAQ:CELU) said on Monday it had appointed Adrian Kilcoyne as the Executive Vice President, Chief Medical Officer (CMO) and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective today. "Kilcoyne will play a fundamental role in advancing our clinical pipeline, including our three Phase 1 studies in acute myeloid leukemia, glioblastoma multiforme and gastric cancer, and one IND-pending program in B-cell malignancies," the company said. Kilcoyne has served as the Chief Medical Officer of Humanigen and Vice President of Global Oncology Evidence Generation and External Alliances in AstraZeneca.
Seeking Alpha • Sep 15

Celularity falls after announcing fund raising deal

The shares of Celularity Inc. (NASDAQ:CELU) dropped more than 10% Thursday after the cell therapy company announced an agreement with an affiliate of the investment manager Yorkville Advisors Global to raise as much as $150M. Per the terms of the deal called Pre-Paid Advance Agreement, CELU is entitled to request up to $80M individual pre-paid advances from Yorkville under certain conditions at a 2% discount and an interest rate of 6%. The deal provides up to $150M of total funding over the next 18 months. However, if there is an outstanding balance of a pre-paid advance over the 18 months, CELU will be required to sell shares of its common stock to Yorkville. The company expects to use the proceeds for working capital and other general corporate purposes. The deal comes after CELU announced an agreement last week to sell up to $150M worth of its common stock in an at-the-market offering.
Seeking Alpha • Sep 08

Celularity falls 10% on deal for $150M common stock offering

The shares of Celularity Inc. (NASDAQ:CELU), a biotech focused on cell therapies, fell ~10% on Thursday after the company announced an agreement to sell up to $150M worth of its common stock in an at-the-market offering. Per the terms of the agreement with BTIG, Oppenheimer, and B. Riley Securities, the company, from time to time, will sell shares of its Class A common stock with a par value of $0.0001 per share and an aggregate offering price of up to $150.0M through the sales agents. CELU is not obligated to sell shares under the agreement, and any decision on sales will be dependent on factors such as market conditions and capital needs, the company said. With its Q2 2022 financials, CELU reported $38M of cash and equivalents as of June 30, following a private placement for ~$27.5M in net cash proceeds.
Seeking Alpha • Jul 27

Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers

Celularity (NASDAQ:CELU) said the first patient had been treated in a phase 1/2a trial with CYNK-101, an investigational genetically modified natural killer (NK) cell therapy to treat cancers. The drug, CYNK-101, was granted both a Fast Track Designation and an Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of human epidermal growth factor receptor 2 (HER2) positive G/GEJ cancer.

Shareholder Returns

CELUUS BiotechsUS Market
7D-18.5%1.5%1.5%
1Y-58.5%41.7%25.5%

Return vs Industry: CELU underperformed the US Biotechs industry which returned 35.5% over the past year.

Return vs Market: CELU underperformed the US Market which returned 26.2% over the past year.

Price Volatility

Is CELU's price volatile compared to industry and market?
CELU volatility
CELU Average Weekly Movement10.5%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: CELU has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CELU's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998123Bob Haririwww.celularity.com

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.

Celularity Inc. Fundamentals Summary

How do Celularity's earnings and revenue compare to its market cap?
CELU fundamental statistics
Market capUS$22.21m
Earnings (TTM)-US$91.67m
Revenue (TTM)US$26.55m
0.8x
P/S Ratio
-0.2x
P/E Ratio

Is CELU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CELU income statement (TTM)
RevenueUS$26.55m
Cost of RevenueUS$20.07m
Gross ProfitUS$6.48m
Other ExpensesUS$98.15m
Earnings-US$91.67m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-3.18
Gross Margin24.39%
Net Profit Margin-345.28%
Debt/Equity Ratio-126.6%

How did CELU perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/12 05:21
End of Day Share Price 2026/05/12 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celularity Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Thomas ShraderBTIG
Swayampakula RamakanthH.C. Wainwright & Co.